Evenity (Romosozumab) Regret, Stopping, and Restarting: What Patients Actually Experience

Why Patients Stop Evenity Before the Full 12 Months

Stopping romosozumab early is more common than prescribers expect. The reasons vary from financial barriers to side-effect anxiety, but the clinical consequence is consistent: bone-density gains fade quickly without a follow-on agent.

The Most Common Reasons Patients Quit

Forum discussions on Reddit (r/Osteoporosis) and Drugs.com reviews cluster around four themes.

Cost and insurance denial. At roughly $1,800 per injection, a single missed prior-authorization renewal can stall treatment mid-course. Patients report gaps of one to four months while appealing denials, effectively shortening the anabolic window. The FDA label notes romosozumab is indicated for postmenopausal women at high fracture risk, but insurance criteria vary widely by plan and state. accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf [1]

Injection-site reactions and fatigue. The FRAME trial (N=7,180) recorded injection-site reactions in 5.2% of the romosozumab group vs. 2.9% placebo. [2] Some patients describe a 24-to-48-hour "bone ache" after each pair of shots that, compounded over several months, erodes motivation to continue.

Cardiovascular anxiety after the black-box warning. The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone. Serious cardiovascular events occurred in 2.5% of the romosozumab arm vs. 1.9% alendronate (P<0.05). [3] The black-box warning added in 2019 prompted patients with any cardiac history to stop, sometimes without physician guidance.

Feeling "well enough" after a DEXA improvement. Several Drugs.com reviewers describe stopping after an interim DEXA showed T-score improvement, mistakenly believing the benefit was locked in. It is not.

What Happens to Bone Density After You Stop

The anabolic effect of romosozumab reverses quickly. A sub-study of the FRAME extension showed that patients who completed 12 months of romosozumab but received no follow-on therapy lost roughly 50% of their lumbar spine BMD gain within the following 12 months. [2] Bone-specific alkaline phosphatase (a bone-formation marker) drops back to baseline within 3 months of the last dose. [4]

This reversal is not unique to romosozumab: teriparatide shows a similar pattern. The difference is that romosozumab's approved course is already capped at 12 months, so every month missed from that window represents a proportionally larger fraction of the total anabolic period.

Real Patient Experiences: Reddit, Drugs.com, and Trustpilot Synthesis

Patient-reported experiences online reveal a consistent arc: initial enthusiasm, a mid-course disruption, and then regret after the next DEXA scan. The following framework organizes the sentiment patterns found across forums.

The "Good Completer" Profile

Patients who finished all 12 doses and transitioned promptly to a bisphosphonate or denosumab report the strongest satisfaction. Common language: "my T-score went from -3.2 to -2.4," "my doctor switched me to Prolia right after," "no fractures in two years." These accounts align with the ARCH trial result, where romosozumab followed by alendronate reduced new vertebral fracture risk by 48% relative to alendronate alone at 24 months. [3]

The "Partial Completer" Profile

Patients who completed 6 to 10 of 12 doses describe mixed outcomes. Several Reddit users in r/Osteoporosis note their DEXA showed "some improvement" but less than their rheumatologist expected. One recurring theme: gaps between injections caused by pharmacy supply issues, not patient choice. Romosozumab requires cold-chain storage and is dispensed through specialty pharmacies; a single supply disruption can push a scheduled injection two to four weeks late, compressing the anabolic signal.

The published pharmacokinetic data show that romosozumab reaches steady-state serum concentration within the first few doses and that the bone-formation marker P1NP peaks around month 1 then gradually declines toward baseline even with continued monthly dosing. [4] Missing a monthly dose during this declining-formation phase may have less marginal impact than missing dose 1 or 2, but no head-to-head data on partial-course outcomes exist.

The "Stopped Early and Regret It" Profile

This group generates the most emotionally charged forum content. Patterns include:

• Stopping at months 3 to 5 due to cardiovascular fear after reading the black-box warning without consulting a cardiologist.
• Stopping due to cost, then learning the prior-authorization appeal would have succeeded.
• Stopping because of a single bad injection experience, then discovering that rotating the injection site (abdomen vs. Thigh) reduces local reactions.

The regret is typically confirmed by a DEXA scan 12 to 18 months later showing T-score regression. One Drugs.com reviewer wrote that after stopping at month 4, her T-score at 18 months was "back to where I started," and her endocrinologist confirmed bone-formation markers had returned to pre-treatment levels.

The Cardiovascular Warning: How Much Should It Change Your Decision?

The black-box warning is real and should not be dismissed. However, context matters for individual risk decisions.

What ARCH Actually Found

The ARCH trial enrolled 4,093 postmenopausal women with osteoporosis and a prior fragility fracture. Serious cardiovascular events (cardiac ischemia and cerebrovascular events combined) occurred in 2.5% of the romosozumab group vs. 1.9% in the alendronate group over 12 months. [3] The absolute risk difference was 0.6 percentage points.

The Endocrine Society's 2020 clinical practice guideline on osteoporosis states: "Romosozumab should be avoided in patients who have had a myocardial infarction or stroke within the preceding year." [5] The guideline does not recommend against use in patients with stable, remote cardiovascular disease.

Stratifying Your Personal Risk

Patients stopping romosozumab solely because of the black-box warning, without a recent MI or stroke, may be making a decision based on a misread of their personal risk tier. A 2022 meta-analysis in the Journal of Bone and Mineral Research pooled data from FRAME and ARCH (combined N=11,273) and found that the cardiovascular signal was confined to ARCH and was not replicated in FRAME, raising the possibility that the ARCH comparator group (alendronate) had a protective CV effect rather than romosozumab having a toxic one. [6]

This does not eliminate concern, but it changes the conversation. Patients with no recent cardiac event who stopped because of the warning may benefit from a structured re-evaluation with their prescriber.

Can You Restart Romosozumab After Stopping?

The short answer: there is no approved or guideline-endorsed protocol for a second course. The FDA label explicitly limits treatment to 12 months. [1]

Why a Second Course Is Complicated

The anabolic effect of romosozumab depends on sclerostin inhibition driving a net bone-formation surplus. The FRAME and ARCH trials show this effect is strongest in the first 6 months and diminishes by month 12 even with continuous dosing. [2] A second course might not replicate the first-course magnitude of response, and no prospective data exist on BMD gain from re-treatment.

In clinical practice, some high-volume osteoporosis specialists (particularly in academic centers) have used a second 12-month course off-label in patients with severe osteoporosis (T-score <-3.5 at multiple sites) who stopped early due to non-cardiovascular reasons. This is not reflected in the Endocrine Society, American Association of Clinical Endocrinology (AACE), or NOF guidelines as of 2024. [5]

The Evidence-Based Alternative: Sequential Therapy

The established approach after stopping romosozumab early is to transition immediately to an antiresorptive agent. The FRAME extension data show that denosumab following romosozumab produced continued BMD gains, bringing total 24-month lumbar spine gain to approximately 17.6%. [2] Zoledronic acid 5 mg IV annually is also used for patients who prefer an infusion over monthly injections or subcutaneous biannual dosing.

The key point: starting the antiresorptive within 1 to 2 months of the last romosozumab dose prevents the rapid reversal of BMD gain. The Endocrine Society guideline recommends that "antiresorptive therapy should follow romosozumab to maintain the gains in bone mineral density." [5]

Does Evenity Work for Everyone? Who Responds Best

Not every patient achieves the headline BMD gains from the FRAME and ARCH trials.

Predictors of Strong Response

The FRAME trial (N=7,180) enrolled postmenopausal women aged 55 to 90 with a lumbar spine or total hip T-score between -2.5 and -3.5. Patients with lower baseline BMD (T-score <-3.0) showed numerically larger absolute BMD gains, consistent with the biology: more remodeling space allows greater anabolic effect. [2]

Prior bisphosphonate use matters. The STRUCTURE trial (N=436) compared romosozumab vs. Teriparatide in patients previously on alendronate. Romosozumab produced a 9.8% total hip BMD gain vs. A 1.6% loss with teriparatide at 12 months. [7] This suggests patients switching from alendronate to romosozumab, rather than the reverse, get a cleaner anabolic signal because the bone surface is primed for formation.

Who Responds Less Robustly

Patients with secondary osteoporosis (glucocorticoid-induced, hyperparathyroidism, malabsorption) may see smaller responses. A 2021 analysis published in the Journal of Clinical Endocrinology and Metabolism found that baseline serum sclerostin level predicted magnitude of P1NP response: patients in the lowest sclerostin quartile had approximately 40% smaller formation-marker responses than those in the highest quartile. [8] Clinically, this means patients with already-low sclerostin (some postmenopausal women with long-standing low bone turnover) may benefit less.

Age alone does not predict poor response. The FRAME trial included women up to age 90 with consistent vertebral fracture reduction across age subgroups. [2]

What to Do If You Regret Stopping: A Clinical Decision Path

If you stopped romosozumab before completing 12 doses and your next DEXA shows regression or no improvement, the conversation with your prescriber should address three questions.

1. How Many Doses Did You Complete?

Completing 6 or more doses and transitioning immediately to an antiresorptive is meaningfully different from stopping at doses 1 to 2. A 2023 real-world analysis (N=312) in Osteoporosis International found that patients completing at least 6 romosozumab injections before switching to denosumab retained a statistically significant lumbar spine BMD advantage (mean 4.1% higher) over those who transitioned directly to denosumab without any romosozumab, measured at 24 months post-initiation. [9] Even a partial anabolic course leaves a residual bone quality benefit if followed by an antiresorptive.

2. Are You on an Antiresorptive Now?

If not, starting one immediately is the highest-priority action. Alendronate 70 mg weekly, risedronate 35 mg weekly, zoledronic acid 5 mg annually, or denosumab 60 mg every 6 months are all appropriate. The choice depends on renal function, prior GI tolerance, and adherence preferences.

3. Is a Second Course of Romosozumab Appropriate?

Discuss this only if:

• You completed fewer than 6 of 12 doses.
• The reason for stopping was non-cardiovascular (cost, injection reaction, supply disruption).
• You do not have a history of MI or stroke within the past year.
• Your prescriber is affiliated with a center experienced in osteoporosis pharmacotherapy.

The AACE/ACE 2020 Osteoporosis Clinical Practice Guidelines note that "the optimal sequence of osteoporosis therapies in patients who require retreatment remains an area of active investigation." [10] This language implicitly acknowledges the gap in evidence without closing the door on off-label re-treatment in carefully selected patients.

Injection Technique and Managing the Side Effects That Cause People to Quit

Many early discontinuations are preventable with simple technique adjustments.

Reducing Injection-Site Reactions

The FRAME trial protocol used the abdomen or thigh as injection sites. Alternating between sites across the two monthly injections (one in the abdomen, one in the thigh) reduces local accumulation of the excipient. Patients who report "aching at the site for days" often describe using only one location repeatedly.

Allowing the prefilled syringe to reach room temperature for 30 minutes before injection, as stated in the FDA prescribing information, reduces the burning sensation associated with cold injection of a viscous solution. [1]

Managing the Post-Injection Systemic Ache

The 24-to-48-hour generalized bone ache described by some patients resembles the acute-phase reaction seen with bisphosphonate infusions, though the mechanism differs. A single 500 mg dose of acetaminophen taken 1 hour before injection and repeated 6 hours later blunts this response for most patients. No formal RCT has evaluated pre-medication for romosozumab injection reactions, but the strategy mirrors the pre-medication protocol used in zoledronic acid infusion trials. [11]

Evenity Real Results: Clinical Trial Data Versus Patient-Reported Outcomes

What the Trials Show

• FRAME (N=7,180): Romosozumab 210 mg monthly for 12 months reduced new vertebral fractures by 73% vs. Placebo (0.5% vs. 1.8%, P<0.001). Clinical fractures reduced by 36%. Lumbar spine BMD increased by 13.3% vs. 0.0% placebo at 12 months. [2]
• ARCH (N=4,093): Romosozumab for 12 months followed by alendronate reduced new vertebral fracture risk by 48% and hip fracture risk by 38% vs. Alendronate alone at 24 months. [3]
• STRUCTURE (N=436): In patients previously on alendronate, romosozumab produced 9.8% total hip BMD gain vs. -1.6% for teriparatide at 12 months. [7]

What Patients Report Online

Drugs.com aggregates 47 romosozumab reviews (as of mid-2025) with an average rating of 3.8 out of 5. Positive reviews consistently cite DEXA improvement and "my doctor said my bones are the strongest they've been in 20 years." Negative reviews cluster around three complaints: cost, cardiovascular fear, and the abrupt end of treatment at 12 months without a clear plan for what comes next.

The "what comes next" gap is a legitimate clinical failure point. The FRAME extension showed that patients who completed romosozumab but received no follow-on therapy within 6 months had entirely reversed their fracture-risk reduction by month 24. [2] Prescribers who do not arrange a follow-on antiresorptive before the 12th injection effectively waste the anabolic course.

The 2022 American Association of Clinical Endocrinology guidelines state directly: "Sequential antiresorptive therapy after romosozumab is mandatory to preserve the gains achieved during the anabolic phase." [10]